drugset / Trial / NCT02722044

Usability of an AI for M923 in Subjects With Moderate to Severe RA

NCT02722044

Phase 3 Completed 33 enrolled Momenta Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the usability of an auto-injector (AI) for the delivery of M923 in patients with rheumatoid arthritis (RA)

Timeline

Start
2016-04
Primary completion
2017-02-21
Completion
2017-02-21

Drugs

EvaluationDrugModalityDoseRoute
Background M923 Monoclonal antibody Subcutaneous

Indications